Brain Dose Burden Is Associated with Treatment-Related Lymphopenia in IDH- Wildtype Glioblastoma: Dosimetric Determinants and Prognostic Impact

Glioblastoma is the most aggressive form of brain cancer in adults. The standard treatment for patients who are strong enough to endure it involves surgery to remove as much of the tumor as possible, followed by a combination of radiation therapy and chemotherapy. While this approach is the best available option, the disease often returns, and long-term survival remains limited. In recent years, doctors have realized that the body's own immune system plays a critical role in how well a patient fights cancer. A key part of this defense is a type of white blood cell called a lymphocyte. These cells circulate through the bloodstream, constantly patrolling for threats. However, lymphocytes are extremely sensitive to radiation. When a patient undergoes radiation therapy for a brain tumor, the beams must pass through healthy brain tissue to reach the cancer. Because the blood vessels in the brain are so dense, a significant portion of the circulating lymphocytes gets caught in the radiation field and is damaged or destroyed. This drop in immune cells, known as lymphopenia, has been linked to worse outcomes for patients, but scientists have struggled to pinpoint exactly which aspects of the radiation treatment cause the most harm.

A team of researchers at the Azienda Ospedaliero-Universitaria Senese in Italy set out to solve this puzzle by looking closely at the relationship between the radiation dose and the immune system in 102 patients with a specific type of glioblastoma. They wanted to know if the size of the tumor itself was the main culprit behind the loss of immune cells, or if it was the way the radiation dose was spread out across the healthy brain. To find out, they examined the medical records of these patients, comparing the radiation plans used for each person with their blood test results taken before treatment started and again when the treatment finished. They also tracked how long the patients survived and whether the cancer returned.

The researchers discovered that the loss of lymphocytes was not simply a matter of how large the tumor was. While the size of the tumor and the area targeted for radiation are naturally linked, the study showed that the tumor size alone did not predict how many immune cells a patient would lose. Instead, the key factor was the total amount of radiation energy deposited into the healthy brain tissue. The team found that patients who received higher average doses of radiation to their whole brain, or who had larger volumes of healthy brain exposed to intermediate levels of radiation, experienced a much sharper decline in their lymphocyte counts. Specifically, the data showed that as the radiation dose to the healthy brain increased, the number of remaining lymphocytes dropped significantly. This relationship held true even after the researchers accounted for other factors that could influence the immune system, such as the use of steroids, the type of chemotherapy given, and the patient's age.

One of the most important findings was that the damage was not caused by just one specific level of radiation, but by a broad range of exposure. The study highlighted that exposure to intermediate doses of radiation—levels that are higher than a tiny background scatter but lower than the intense dose given directly to the tumor—was particularly damaging to the immune system. The researchers measured this using various metrics, such as the volume of the brain receiving a certain dose, and found that these metrics were consistent predictors of immune cell loss. They also found that the total energy delivered to the brain, calculated by multiplying the average dose by the volume of the brain, was a strong indicator of how much the immune system would be suppressed. This suggests that the way the radiation beams are arranged and how they spill over into healthy tissue matters more than the sheer size of the target area.

The consequences of this immune suppression were severe. The study found that patients who experienced a significant drop in their lymphocyte counts, defined as a moderate to severe decline, had much shorter survival times and were more likely to see their cancer progress compared to those who maintained better immune levels. Patients with this level of immune suppression had a median overall survival of less than ten months, whereas those with better-preserved immune counts lived for more than a year and a half on average. This link was independent of other known risk factors, such as the genetic makeup of the tumor or how much of it was removed during surgery. It appears that the radiation-induced damage to the immune system creates a vulnerability that allows the cancer to grow back more aggressively or makes the patient less able to tolerate further treatment.

These results offer a new perspective on how radiation therapy for brain cancer might be improved. The study suggests that while it is impossible to avoid exposing some healthy brain tissue to radiation, the focus should shift toward minimizing the unnecessary intermediate dose to the rest of the brain. This does not mean reducing the dose to the tumor itself, which must remain high to kill the cancer. Instead, it points to the need for more precise planning techniques that can confine the radiation more tightly to the target area, sparing the surrounding healthy brain from the cumulative dose that harms the immune system. The researchers propose that future treatments should be designed with the goal of preserving the body's immune competence, potentially by using advanced technologies that can shape the radiation beams more accurately. By protecting the lymphocytes, doctors may be able to improve the overall outcome for patients, giving their bodies a better chance to fight the disease alongside the medical treatment.